Llwytho...
RAS and BRAF in metastatic colorectal cancer management
The treatment of metastatic colorectal cancer (mCRC) has been further refined with the development of monoclonal antibodies, cetuximab and panitumumab, towards the epidermal growth factor receptor (EGFR). Anti-EGFR therapy has afforded improved survival in those with wild-type RAS mCRC but provides...
Wedi'i Gadw mewn:
| Cyhoeddwyd yn: | J Gastrointest Oncol |
|---|---|
| Prif Awduron: | , , |
| Fformat: | Artigo |
| Iaith: | Inglês |
| Cyhoeddwyd: |
AME Publishing Company
2016
|
| Pynciau: | |
| Mynediad Ar-lein: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5056249/ https://ncbi.nlm.nih.gov/pubmed/27747083 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.21037/jgo.2016.06.12 |
| Tagiau: |
Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!
|